Table of Contents

HK J Paediatr (New Series)
Vol 24. No. 1, 2019

HK J Paediatr (New Series) 2019;24:25-32

Original Article

Antiemetics to Control Vomiting in Children: A Double-Blind Placebo-Controlled Trial

O Karakayali, S Yilmaz, YS Divriklioglu, Y Yigit, HC Halhalli


Aim: The goal of this investigation was to prospectively compare the efficacy of ondansetron, metoclopramide and a placebo in children presenting to the emergency department with acute vomiting. Materials and Methods: In this randomised double-blind trial, the participants, who were younger than 18 years of age, were randomly assigned to receive treatment with (a) 0.15 mg/kg intravenous ondansetron, (b) 0.2 mg/kg intravenous metoclopramide in 100 mL normal saline, and (c) 100 mL normal saline as a placebo. The primary outcome was measured as recurrence of vomiting after 60 minutes subsequent to antiemetic therapy. Results: A total of 234 patients were randomised into the three treatment groups with (a) ondansetron (n=77), (b) metoclopramide (n=79) and (c) placebo (n=78). The median age was 68.27±39.97 months, and 49.1% were male. The results showed the occurrence of vomiting within the first 60 minutes was significantly different in the three groups (p=0.001), but there was no difference between the ondansetron and metoclopramide groups (p=0.557). The 30th, 120th, and the 240th minute results were statistically significant among the treatment groups (p=0.002, p=0.000, p=0.000 respectively), but there were no difference between ondansetron and metoclopramide (p=0.357, p=0.188, p=0.126, respectively). Extrapyramidal symptoms were found in 1 patient in the metoclopramide group (1.3%). There was no difference among the 3 treatment groups in terms of vomiting during the 24-hour follow-up (p=0.200). Conclusion: Intravenous single-dose slow infusion of antiemetics is effective in controlling vomiting compared to placebo.

Keyword : Antiemetics; Emergency Medicine; Paediatrics; Vomiting

Abstract in Chinese


This web site is sponsored by Johnson & Johnson (HK) Ltd.
©2022 Hong Kong Journal of Paediatrics. All rights reserved. Developed and maintained by Medcom Ltd.